Theo de Reijke

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7492782/publications.pdf

Version: 2024-02-01

107	3,321	212478	190340
papers	citations	28	53
		h-index	g-index

115	115	115	4509
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Multiparametric Magnetic Resonance Imaging for the Detection of Clinically Significant Prostate Cancer: What Urologists Need to Know. Part 4: Transperineal Magnetic Resonanceâ€“Ultrasound Fusion Guided Biopsy Using Local Anesthesia. European Urology, 2022, 81, 110-117.	0.9	17
2	Advancements in the identification of EV derived mRNA biomarkers for liquid biopsy of clear cell renal cell carcinomas. Urology, 2022, 160, 87-93.	0.5	7
3	Predictors of clinically significant prostate cancer in biopsy-naÃ¯ve and prior negative biopsy men with a negative prostate MRI: improving MRI-based screening with a novel risk calculator. Therapeutic Advances in Urology, 2022, 14, 175628722210885.	0.9	3
4	The effect of metformin on bladder cancer incidence and outcomes â€“a systematic review and meta-analysis. Bladder Cancer, 2022, , 1-18.	0.2	1
5	A Multicenter Retrospective Cohort Series of Muscle-invasive Bladder Cancer Patients Treated with Definitive Concurrent Chemoradiotherapy in Daily Practice. European Urology Open Science, 2022, 39, 7-13.	0.2	3
6	Safety and Feasibility of Soractelite Transperineal Focal Laser Ablation for Prostate Cancer and Short-term Quality of Life Analysis from a Multicenter Pilot Study. European Urology Open Science, 2022, 39, 48-54.	0.2	5
7	Bladder-Sparing Chemoradiotherapy Combined with Immune Checkpoint Inhibition for Locally Advanced Urothelial Bladder Cancerâ€”A Review. Cancers, 2022, 14, 38.	1.7	16
8	High-dose Radiotherapy or Androgen Deprivation Therapy (HEAT) as Treatment Intensification for Localized Prostate Cancer: An Individual Patientâ€“data Network Meta-analysis from the MARCAP Consortium. European Urology, 2022, 82, 106-114.	0.9	19
9	A scalable hyperthermic intravesical chemotherapy (HIVEC) setup for rat models of bladder cancer. Scientific Reports, 2022, 12, 7017.	1.6	4
10	Outcomes of salvage radical prostatectomy after initial irreversible electroporation treatment for recurrent prostate cancer. BJU International, 2022, 130, 611-618.	1.3	5
11	Diagnostic Accuracy of Multiparametric Magnetic Resonance Imaging to Detect Residual Prostate Cancer Following Irreversible Electroporationâ€”A Multicenter Validation Study. European Urology Focus, 2022, 8, 1591-1598.	1.6	6
12	Image-guided in-Vivo Needle-Based Confocal Laser Endomicroscopy in the Prostate: Safety and Feasibility Study in 2 Patients. Technology in Cancer Research and Treatment, 2022, 21, 153303382210931.	0.8	0
13	Management of patients who opt for radical prostatectomy during the coronavirus disease 2019 (COVIDâ€19) pandemic: an international accelerated consensus statement. BJU International, 2021, 127, 729-741.	1.3	9
14	Profiling the proteoforms of urinary prostate-specific antigen by capillary electrophoresis â€“ mass spectrometry. Journal of Proteomics, 2021, 238, 104148.	1.2	12
15	Defining candidate mRNA and protein EV biomarkers to discriminate ccRCC and pRCC from non-malignant renal cells in vitro. Medical Oncology, 2021, 38, 105.	1.2	5
16	Validation of Confocal Laser Endomicroscopy Features of Bladder Cancer: The Next Step Towards Real-time Histologic Grading. European Urology Focus, 2020, 6, 81-87.	1.6	26
17	Local Failure and Survival After Definitive Radiotherapy for Aggressive Prostate Cancer: An Individual Patient-level Meta-analysis of Six Randomized Trials. European Urology, 2020, 77, 201-208.	0.9	37
18	The Feasibility and Utility of Cystoscopy-Guided Hydrogel Marker Placement in Patients With Muscle-Invasive Bladder Cancer. Practical Radiation Oncology, 2020, 10, 195-201.	1.1	5

#	Article	IF	Citations
19	EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancerâ€"An International Collaborative Multistakeholder Effortâ€. European Urology, 2020, 77, 223-250.	0.9	132
20	The Diagnostic Yield and Concordance of Ureterorenoscopic Biopsies for Grading of Upper Tract Urothelial Carcinoma: A Dutch Nationwide Analysis. Journal of Endourology, 2020, 34, 907-913.	1.1	11
21	The Successful Return-To-Work Questionnaire for Cancer Survivors (I-RTW_CS): Development, Validity and Reproducibility. Patient, 2020, 13, 567-582.	1.1	11
22	Detection of extracellular vesicles in plasma and urine of prostate cancer patients by flow cytometry and surface plasmon resonance imaging. PLoS ONE, 2020, 15, e0233443.	1.1	17
23	Extracellular vesicle isolation from human renal cancer tissue. Medical Oncology, 2020, 37, 28.	1.2	23
24	ECCO Essential Requirements for Quality Cancer Care: Prostate cancer. Critical Reviews in Oncology/Hematology, 2020, 148, 102861.	2.0	29
25	Detection of clinically significant prostate cancer in biopsyâ€naÃ¯ve men: direct comparison of systematic biopsy, multiparametric MRIâ€and contrastâ€ultrasoundâ€dispersion imagingâ€targeted biopsy. BJU International, 2020, 126, 481-493.	1.3	17
26	Comprehensive evaluation of methods for small extracellular vesicles separation from human plasma, urine and cell culture medium. Journal of Extracellular Vesicles, 2020, 10, e12044.	5.5	97
27	The Role of Fluorescence In Situ Hybridization for Predicting Recurrence after Adjuvant bacillus Calmette-GuÃ©rin in Patients with Intermediate and High Risk Nonmuscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis of Individual Patient Data. Journal of Urology, 2020, 203, 283-291.	0.2	10
28	Transperineal Laser Ablation Treatment for Lower Urinary Tract Symptoms Due to Benign Prostatic Obstruction: Protocol for a Prospective In Vivo Pilot Study. JMIR Research Protocols, 2020, 9, e15687.	0.5	14
29	Hyperthermia Treatment Planning Including Convective Flow in Cerebrospinal Fluid for Brain Tumour Hyperthermia Treatment Using a Novel Dedicated Paediatric Brain Applicator. Cancers, 2019, 11, 1183.	1.7	26
30	The First In Vivo Needleâ€Based Optical Coherence Tomography in Human Prostate: A Safety and Feasibility Study. Lasers in Surgery and Medicine, 2019, 51, 390-398.	1.1	9
31	Recent advances in extracellular vesicle research for urological cancers: From technology to application. Biochimica Et Biophysica Acta: Reviews on Cancer, 2019, 1871, 342-360.	3.3	16
32	EAUâ€"ESMO consensus statements on the management of advanced and variant bladder cancerâ€"an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees. Annals of Oncology, 2019, 30, 1697-1727.	0.6	96
33	Study protocol of a phase II clinical trial of oral metformin for the intravesical treatment of non-muscle invasive bladder cancer. BMC Cancer, 2019, 19, 1133.	1.1	14
34	Association of Gleason Grade With Androgen Deprivation Therapy Duration and Survival Outcomes. JAMA Oncology, 2019, 5, 91.	3.4	27
35	Nationwide treatment patterns and survival of older patients with prostate cancer. Journal of Geriatric Oncology, 2019, 10, 252-258.	0.5	19
36	The added value of systematic biopsy in men with suspicion of prostate cancer undergoing multiparametric MRI-targeted biopsy. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 298.e1-298.e9.	0.8	26

#	Article	IF	Citations
37	Fluorescence in situ hybridization in 1ÂmL of selective urine for the detection of upper tract urothelial carcinoma: a feasibility study. Medical Oncology, 2019, 36, 10.	1.2	6
38	Metastatic prostate cancer remains incurable, why?. Asian Journal of Urology, 2019, 6, 26-41.	0.5	103
39	Preliminary Diagnostic Accuracy of Multiparametric Magnetic Resonance Imaging to Detect Residual Prostate Cancer Following Focal Therapy with Irreversible Electroporation. European Urology Focus, 2019, 5, 585-591.	1.6	27
40	An In-Depth Glycosylation Assay for Urinary Prostate-Specific Antigen. Analytical Chemistry, 2018, 90, 4414-4421.	3.2	54
41	Monopolar vs. bipolar transurethral resection for nonâ€“muscle invasive bladder carcinoma: A post-hoc analysis from a randomized controlled trial. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 338.e1-338.e11.	0.8	21
42	Pair-matched patient-reported quality of life and early oncological control following focal irreversible electroporation versus robot-assisted radical prostatectomy. World Journal of Urology, 2018, 36, 1383-1389.	1.2	28
43	Guideline of guidelines: primary monotherapies for localised or locally advanced prostate cancer. BJU International, 2018, 122, 535-548.	1.3	19
44	Analogous detection of circulating tumor cells using the AccuCyte^{Â®}â€”CyteFinder^{Â®} system and ISET system in patients with locally advanced and metastatic prostate cancer. Prostate, 2018, 78, 300-307.	1.2	19
45	Reduce bladder cancer recurrence in patients treated for upper urinary tract urothelial carcinoma: The REBACARE-trial. Contemporary Clinical Trials Communications, 2018, 9, 121-129.	0.5	16
46	The Current State of Predicting Response on Bacillus Calmette-GuÃ©rin Treatment for Nonmuscle Invasive Bladder Cancer is Not Yet Useful for Patients but Attributes to Understanding Its Mechanisms of Action. European Urology, 2018, 73, 749-750.	0.9	5
47	Clinical validation of a novel thermophysical bladder model designed to improve the accuracy of hyperthermia treatment planning in the pelvic region. International Journal of Hyperthermia, 2018, 35, 383-397.	1.1	11
48	The effect of air pockets in the urinary bladder on the temperature distribution during loco-regional hyperthermia treatment of bladder cancer patients. International Journal of Hyperthermia, 2018, 35, 441-449.	1.1	3
49	Emerging intravesical drugs for the treatment of non muscle-invasive bladder cancer. Expert Opinion on Emerging Drugs, 2018, 23, 135-147.	1.0	10
50	Confocal Laser Endomicroscopy for the Diagnosis of Urothelial Carcinoma in the Bladder and the Upper Urinary Tract. Videourology (New Rochelle, N Y), 2018, 32, .	0.1	3
51	Confocal Laser Endomicroscopy for the Diagnosis of Urothelial Carcinoma in the Bladder and the Upper Urinary Tract: Protocols for Two Prospective Explorative Studies. JMIR Research Protocols, 2018, 7, e34.	0.5	13
52	Confocal Laser Endomicroscopy and Optical Coherence Tomography for the Diagnosis of Prostate Cancer: A Needle-Based, In Vivo Feasibility Study Protocol (IDEAL Phase 2A). JMIR Research Protocols, 2018, 7, e132.	0.5	7
53	Ex-vivo study in nephroureterectomy specimens defining the role of 3-D upper urinary tract visualization using optical coherence tomography and endoluminal ultrasound. Journal of Medical Imaging, 2018, 5, 1.	0.8	3
54	A surface tension magnetophoretic device for rare cell isolation and characterization. Medical Oncology, 2017, 34, 22.	1.2	5

#	Article	IF	Citations
55	Firstâ€line nonâ€cytotoxic therapy in chemotherapyâ€naive patients with metastatic castrationâ€resistant prostate cancer: a systematic review of 10 randomised clinical trials. BJU International, 2017, 119, 831-845.	1.3	14
56	Editorial Comment. Journal of Urology, 2017, 197, 1417-1417.	0.2	0
57	Re: Ten-year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer. European Urology, 2017, 71, 491-492.	0.9	2
58	The efficacy of Apaziquone in the treatment of bladder cancer. Expert Opinion on Pharmacotherapy, 2017, 18, 1781-1788.	0.9	12
59	Improving postoperative radiotherapy following radical prostatectomy. Expert Review of Anticancer Therapy, 2017, 17, 925-937.	1.1	0
60	Second-line therapy in patients with metastatic castration-resistant prostate cancer with progression after or under docetaxel: A systematic review of nine randomized controlled trials. Seminars in Oncology, 2017, 44, 358-371.	0.8	13
61	Utilization of multiparametric prostate magnetic resonance imaging in clinical practice and focal therapy: report from a Delphi consensus project. World Journal of Urology, 2017, 35, 695-701.	1.2	63
62	Current position of diagnostics and surgical treatment for upper tract urothelial carcinoma. Minerva Urology and Nephrology, 2017, 69, 159-165.	1.3	4
63	Fluorescence in situ hybridization as prognostic predictor of tumor recurrence during treatment with Bacillus Calmetteâ€“GuÃ©rin therapy for intermediate- and high-risk non-muscle-invasive bladder cancer. Medical Oncology, 2017, 34, 172.	1.2	19
64	Non-invasive prostate cancer detection by measuring miRNA variants (isomiRs) in urine extracellular vesicles. Oncotarget, 2016, 7, 22566-22578.	0.8	113
65	Dynamic contrastâ€enhanced ultrasound parametric imaging for the detection of prostate cancer. BJU International, 2016, 117, 598-603.	1.3	43
66	Increasing age is not associated with toxicity leading to discontinuation of treatment in patients with urothelial nonâ€muscleâ€invasive bladder cancer randomised to receive 3 years of maintenance bacille Calmetteâ€“GuÃ©rin: results from European Organisation for Research and Treatment of Cancer Genitoâ€Urinary Group study 30911. BJU International, 2016, 118, 423-428.	1.3	28
67	Improving hyperthermia treatment planning for the pelvis by accurate fluid modeling. Medical Physics, 2016, 43, 5442-5452.	1.6	17
68	Histopathological Outcomes after Irreversible Electroporation for Prostate Cancer: Results of an Ablate and Resect Study. Journal of Urology, 2016, 196, 552-559.	0.2	42
69	Chemohyperthermia in non-muscle-invasive bladder cancer: An overview of the literature and recommendations. International Journal of Hyperthermia, 2016, 32, 363-373.	1.1	29
70	Prostate cancer diagnosis by optical coherence tomography: First results from a needle based optical platform for tissue sampling. Journal of Biophotonics, 2016, 9, 490-498.	1.1	24
71	MRI and contrast-enhanced ultrasound imaging for evaluation of focal irreversible electroporation treatment: results from a phase I-II study in patients undergoing IRE followed by radical prostatectomy. European Radiology, 2016, 26, 2252-2260.	2.3	55
72	The correlation between the electrode configuration and histopathology of irreversible electroporation ablations in prostate cancer patients. World Journal of Urology, 2016, 34, 657-664.	1.2	56

#	Article	IF	Citations
73	EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Nonâ€“Muscle-invasive Stage Taâ€“T1 Urothelial Bladder Cancer Patients Treated with 1â€“3 Years of Maintenance Bacillus Calmette-GuÃ©rin. European Urology, 2016, 69, 60-69.	0.9	445
74	Appropriate antibiotic use for patients with complicated urinary tract infections in 38 Dutch Hospital Departments: a retrospective study of variation and determinants. BMC Infectious Diseases, 2015, 15, 505.	1.3	12
75	Prostate cancer diagnosis: the feasibility of needle-based optical coherence tomography. Journal of Medical Imaging, 2015, 2, 037501.	0.8	28
76	Routine urinalysis in patients with a blunt abdominal trauma mechanism is not valuable to detect urogenital injury. Emergency Medicine Journal, 2015, 32, 119-123.	0.4	12
77	Combining Mitomycin C and Regional 70 MHz Hyperthermia in Patients with Nonmuscle Invasive Bladder Cancer: A Pilot Study. Journal of Urology, 2015, 194, 1202-1208.	0.2	37
78	A systematic review of randomised controlled trials of radiotherapy for localised prostate cancer. European Journal of Cancer, 2015, 51, 2345-2367.	1.3	81
79	A Cluster-Randomized Trial of Two Strategies to Improve Antibiotic Use for Patients with a Complicated Urinary Tract Infection. PLoS ONE, 2015, 10, e0142672.	1.1	15
80	The safety and efficacy of irreversible electroporation for the ablation of prostate cancer: a multicentre prospective human in vivo pilot study protocol. BMJ Open, 2014, 4, e006382.	0.8	48
81	Differences in Time to Disease Progression Do Not Predict for Cancer-specific Survival in Patients Receiving Immediate or Deferred Androgen-deprivation Therapy for Prostate Cancer: Final Results of EORTC Randomized Trial 30891 with 12 Years of Follow-up. European Urology, 2014, 66, 829-838.	0.9	56
82	The Effect of Age on the Efficacy of Maintenance Bacillus Calmette-GuÃ©rin Relative to Maintenance Epirubicin in Patients with Stage Ta T1 Urothelial Bladder Cancer: Results from EORTC Genito-Urinary Group Study 30911. European Urology, 2014, 66, 694-701.	0.9	68
83	Optimal management of metastatic castration-resistant prostate cancer: Highlights from a European Expert Consensus Panel. European Journal of Cancer, 2014, 50, 1617-1627.	1.3	133
84	Complications of prostate biopsy. Expert Review of Anticancer Therapy, 2013, 13, 829-837.	1.1	21
85	Follow-up procedures for non-muscle-invasive bladder cancer: an update. Expert Review of Anticancer Therapy, 2012, 12, 1229-1241.	1.1	17
86	GreenLightâ„¢ laser in the treatment of lower urinary tract symptoms due to benign prostatic enlargement. Expert Review of Medical Devices, 2011, 8, 139-147.	1.4	1
87	Is age a prognostic factor for treatment outcome in renal cell cancerâ€”A comprehensive review. Critical Reviews in Oncology/Hematology, 2009, 72, 83-89.	2.0	3
88	EORTC-GU group expert opinion on metastatic renal cell cancer. European Journal of Cancer, 2009, 45, 765-773.	1.3	103
89	Treatment of local progression following radiotherapy. European Journal of Cancer, 2009, 45, 140-147.	1.3	0
90	Editorial Comment on: Three-Year Outcome following Holmium Laser Enucleation of the Prostate Combined with Mechanical Morcellation in 330 Consecutive Patients. European Urology, 2008, 53, 604-605.	0.9	0

#	Article	IF	Citations
91	Fluorescencein situhybridization: a multitarget approach in diagnosis and management of urothelial cancer. Expert Review of Molecular Diagnostics, 2007, 7, 11-19.	1.5	20
92	BACILLUS CALMETTE-GUERIN VERSUS EPIRUBICIN FOR PRIMARY, SECONDARY OR CONCURRENT CARCINOMA IN SITU OF THE BLADDER: RESULTS OF A EUROPEAN ORGANIZATION FOR THE RESEARCH AND TREATMENT OF CANCERâ€"GENITO-URINARY GROUP PHASE III TRIAL (30906). Journal of Urology, 2005, 173, 405-409.	0.2	98
93	Comparative efficacy of two Î±1-adrenoreceptor antagonists, doxazosin and alfuzosin, in patients with lower urinary tract symptoms from benign prostatic enlargement. BJU International, 2004, 93, 757-762.	1.3	34
94	Long-term complications of brachytherapy in local prostate cancer. BJU International, 2003, 92, 869-873.	1.3	5
95	Rectal Squamous Cell Carcinoma 11 Years After Brachytherapy For Carcinoma Of The Prostate. Journal of Urology, 2003, 169, 280-280.	0.2	31
96	Prognostic Factor Analysis in Patients with Advanced Prostate Cancer Treated by Castration Plus Anandron or Placebo: A Final Update. European Urology, 2002, 42, 139-146.	0.9	8
97	EORTC prostate cancer trials: what have we learnt?. Critical Reviews in Oncology/Hematology, 2002, 43, 159-165.	2.0	2
98	LOCAL TRACT METASTASIS OF PROSTATIC ADENOCARCINOMA 8 YEARS AFTER 125 IODINE BRACHYTHERAPY. Journal of Urology, 2001, 166, 995-995.	0.2	2
99	URINARY INTERLEUKIN-2 MONITORING DURING PROLONGED BACILLUS CALMETTE-GUERIN TREATMENT: CAN IT PREDICT THE OPTIMAL NUMBER OF INSTILLATIONS?. Journal of Urology, 1999, 161, 67-71.	0.2	38
100	RE: QUANTITATIVE POLYMERASE CHAIN REACTION DOES NOT IMPROVE PREOPERATIVE PROSTATE CANCER STAGING: A CLINICOPATHOLOGICAL MOLECULAR ANALYSIS OF 121 PATIENTS. Journal of Urology, 1998, 159, 1311-1312.	0.2	26
101	Intermittent androgen deprivation in advanced prostate cancer. Urological Research, 1997, 25, S63-S66.	1.5	4
102	Urinary Cytokines During Intravesical Bacillus Calmetteguerin Therapy for Superficial Bladder Cancer: Processing, Stability and Prognostic Value. Journal of Urology, 1996, 155, 477-482.	0.2	157
103	Urinary cytokines during intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer: processing, stability and prognostic value. Journal of Urology, 1996, 155, 477-82.	0.2	49
104	Incidental carcinoma of the prostate. Journal of Surgical Oncology, 1995, 11, 36-45.	1.4	35
105	Tumor growth delay by laser-generated shock waves. Lasers in Surgery and Medicine, 1994, 14, 205-212.	1.1	4
106	Cytokine production by the human bladder carcinoma cell line T24 in the presence of bacillus Calmette-Guerin (BCG). Urological Research, 1993, 21, 349-352.	1.5	53
107	Laser lithotripsy with a 504 nm pulsed dye laser: in vitro fragmentation related to stone weight and pulse energy. Lasers in Medical Science, 1990, 5, 65-69.	1.0	3